STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early
In data released at ESMO, the Moderna-Merck personalized mRNA cancer vaccine reduced recurrence-free survival and the time until distant metastasis occurred.
The European Society for Medical Oncology conference kicked off in Madrid with an unexpected twist as the most anticipated data leaked before it was officially presented. The focus was on the highly awaited Moderna-Merck melanoma cancer vaccine data, which arrived earlier than expected. This development caught reporters off guard, disrupting their meticulously planned coverage of the conference.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
